Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Two molecular forms of Peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1–36 and PYY 3–36
It is demonstrated the existence of two forms of PYY in human blood, coeluting with synthetic PYY-I and Pyy-II, using this radioimmunoassay and reversed phase HPLC. Expand
A comparison of budesonide with prednisolone for active Crohn's disease.
- P. Rutgeerts, R. Löfberg, +7 authors H. Lorenz‐Meyer
- The New England journal of medicine
- 29 September 1994
In this trial, prednisolone reduced scores on the Crohn's disease activity index more, whereas with budesonide there were fewer glucocorticoid-associated side effects and less suppression of pituitary-adrenal function. Expand
Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial.
This study detected no benefit of antibiotic prophylaxis with respect to the risk of developing infected pancreatic necrosis and switched to open antibiotic treatment when infectious complications, multiple organ failure sepsis, or systemic inflammatory response syndrome occurred. Expand
A new molecular form of PYY: Structural characterization of human PYY(3–36) and PYY(1–36)
Its high proportions in the colon suggest that it is released into the circulation where it could act as a partial antagonist of PYY(1-36) and may differ in its biological activity from the intact peptide. Expand
European cooperative Crohn's disease study (ECCDS) : Results of drug treatment
Abstract A multicenter double-blind study of the effectiveness of sulfasalazine and 6-methylprednisolone, alone and in combination, was conducted on 452 patients with Crohn's disease. One hundred… Expand
European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment.
Continual administration of low doses of 6-methylprednisolone, or the combination regimen, was beneficial in patients who responded initially to treatment of active disease, and the addition of sulfasalazine offered no advantage. Expand
Ileal release of glucagon-like peptide-1 (GLP-1)
- P. Layer, J. Juul Holst, D. Grandt, H. Goebell
- Biology, Medicine
- Digestive Diseases and Sciences
- 1 May 1995
The hypothesis that the distal small intestine may participate in the late postprandial inhibitory regulation of gastric secretory function in humans and that GLP-1 may be an intermediary factor is supported. Expand
Novel generation of hormone receptor specificity by amino terminal processing of peptide YY.
- D. Grandt, S. Teyssen, +7 authors H. Goebell
- Biology, Medicine
- Biochemical and biophysical research…
- 14 August 1992
It is shown that PYY-II is as potent as PYY for the inhibition of pancreatic secretion, which must occur through Y2 receptors, and Amino terminal processing of PYY represents a novel type of regulation of peptide hormone specificity. Expand
Reduced Bone Mineral Density and Unbalanced Bone Metabolism in Patients with Inflammatory Bowel Disease
Evidence for an increased bone resorption accompanied by low bone formation in IBD patients is provided, suggesting an imbalance of bonc metabolism is likely to be one of the reasons for increased bone loss in I BD patients. Expand
Delivery and fate of oral mesalamine microgranules within the human small intestine.
Although the major part of continuous-release mesalamine is delivered to the colon, large proportions are liberated and available at high concentrations within the small intestinal lumen, thus explaining its therapeutic efficacy in small intestinal Crohn's disease. Expand